ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA approves Merz’s Xeomin for sialorrhea
pharmaceutical-technology
July 12, 2018The US Food and Drug Administration (FDA) has approved Merz North America’s supplemental biologics license application for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, otherwise known as excessive drooling.
Pharma Sources Insight January 2025
